InnoCare Pharma Limited
INCPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -84.6% | -8.2% | 22.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 87.4% | 88.4% | 90.5% | 87% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -21.8% | -13.5% | 4.3% | -53.2% |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -8.9% | -13.7% | 4.7% | -53% |
| EPS | -0.003 | -0.04 | 0.01 | -0.1 |
| % Growth | 93.2% | -496% | 110% | – |
| EPS Diluted | -0.003 | -0.04 | 0.01 | -0.1 |
| Weighted Avg Shares Out | 2 | 1 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 1 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -4.9% | -25.3% | -0.9% | -39% |